NEXTBio Capital Management LP Makes New $3.40 Million Investment in Cogent Biosciences, Inc. $COGT

Posted by Brenda Bartman on Jun 14th, 2026

NEXTBio Capital Management LP bought a new position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 95,819 shares of the technology company’s stock, valued at approximately $3,403,000. Cogent Biosciences comprises 2.0% of NEXTBio Capital Management LP’s holdings, making the stock its 18th largest holding.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its holdings in Cogent Biosciences by 1,164.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 708 shares of the technology company’s stock worth $25,000 after buying an additional 652 shares during the last quarter. Global Retirement Partners LLC bought a new position in Cogent Biosciences during the fourth quarter worth about $37,000. PNC Financial Services Group Inc. boosted its holdings in Cogent Biosciences by 414.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,281 shares of the technology company’s stock worth $46,000 after buying an additional 1,032 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Cogent Biosciences by 91.7% during the fourth quarter. GAMMA Investing LLC now owns 1,369 shares of the technology company’s stock worth $49,000 after buying an additional 655 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in Cogent Biosciences by 35.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the technology company’s stock worth $66,000 after buying an additional 488 shares during the last quarter.

Cogent Biosciences Trading Up 1.5%

NASDAQ:COGT opened at $33.10 on Friday. Cogent Biosciences, Inc. has a fifty-two week low of $6.88 and a fifty-two week high of $43.73. The company has a debt-to-equity ratio of 0.41, a current ratio of 15.14 and a quick ratio of 15.14. The stock has a market capitalization of $5.66 billion, a PE ratio of -15.25 and a beta of 0.34. The business’s 50-day simple moving average is $34.62 and its 200-day simple moving average is $36.58.

Cogent Biosciences (NASDAQ:COGT – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The technology company reported ($0.53) earnings per share for the quarter, meeting the consensus estimate of ($0.53). Sell-side analysts expect that Cogent Biosciences, Inc. will post -2.26 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

COGT has been the topic of a number of recent analyst reports. Wedbush restated an “outperform” rating and set a $55.00 target price on shares of Cogent Biosciences in a report on Friday, May 29th. HC Wainwright raised their target price on Cogent Biosciences to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Robert W. Baird set a $35.00 target price on Cogent Biosciences in a report on Thursday, February 19th. Piper Sandler raised their target price on Cogent Biosciences from $39.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cogent Biosciences in a report on Friday, April 10th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.73.

Check Out Our Latest Stock Report on COGT

Cogent Biosciences Company Profile

(Free Report)

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.